NCT04623710 - Study of ALXN2050 in Participants With Renal Impairment | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 8, 2021

Primary Completion Date

February 18, 2022

Study Completion Date

March 21, 2022

Conditions

Renal ImpairmentHealthy

Interventions

DRUG

ALXN2050

ALXN2050 (120 milligrams) will be administered orally twice daily on Days 1 through 3, with an additional dose (120 milligrams) administered orally on the morning of Day 4.

Trial Locations (2)

32809

Clinical Trial Site, Orlando

33014

Clinical Trial Site, Hialeah